<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="Cache-Control" content="no-cache, no-store, must-revalidate">
    <meta http-equiv="Pragma" content="no-cache">
    <meta http-equiv="Expires" content="0">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Resources - CRLM LT Clinical Resource</title>
    <link rel="stylesheet" href="../css/style.css?v=1765115033437">
</head>
<body>
    <!-- Navigation -->
    <nav class="navbar">
        <div class="container">
            <div class="logo">CRLM LT Resource</div>
            <button class="hamburger" id="hamburger" aria-label="Toggle menu">
                <span></span>
                <span></span>
                <span></span>
            </button>
            <ul class="nav-menu" id="navMenu">
                <li><a href="../index.html">Home</a></li>
                <li><a href="overview.html">Overview</a></li>
                <li><a href="selection-criteria.html">Selection Criteria</a></li>
                <li><a href="outcomes.html">Clinical Outcomes</a></li>
                <li><a href="tools.html">Tools</a></li>
                <li><a href="faq.html">FAQ</a></li>
                <li><a href="glossary.html">Glossary</a></li>
                <li><a href="case-studies.html">Cases</a></li>
                <li><a href="bridging-therapy.html">Bridging Therapy</a></li>
                <li><a href="lt-vs-resection.html">LT vs Resection</a></li>
                <li><a href="survival-curves.html">Survival Curves</a></li>
                <li><a href="pdf-resources.html">PDF Resources</a></li>
                <li><a href="patient-flowchart.html">Patient Flowchart</a></li>
                <li><a href="resources.html" class="active">Resources</a></li>
                <li><a href="about-research-group.html">About Research Group</a></li>
            </ul>
        </div>
    </nav>

    <!-- Main Content -->
    <main class="content">
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">Home</a> / Resources
            </div>

            <h1>Resources and References</h1>

            <section class="section">
                <h2>Key Guidelines and Consensus Documents</h2>
                
                <div class="resource-item">
                    <h3>IHPBA Consensus Guidelines (2021)</h3>
                    <p><strong>Title:</strong> Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines</p>
                    <p><strong>Authors:</strong> Bonney GK, Chew CA, Lodge P, et al.</p>
                    <p><strong>Journal:</strong> The Lancet Gastroenterology & Hepatology, 2021; 6(11):933-946</p>
                    <p><strong>Significance:</strong> Comprehensive consensus document establishing 44 statements on patient selection, biological behavior, graft selection, recipient considerations, and outcomes. Essential reading for all teams considering LT for CRLM.</p>
                </div>

                <div class="resource-item">
                    <h3>Expanding Indications in Transplant Oncology (2024)</h3>
                    <p><strong>Title:</strong> Liver Transplant for Nonhepatocellular Carcinoma Tumors: A Review of Expanding Indications in Nontraditional Transplant Oncology</p>
                    <p><strong>Authors:</strong> Wehrle CJ, Fares S, Shanmugarajah K, et al.</p>
                    <p><strong>Journal:</strong> Digestive Disease Interventions, 2024</p>
                    <p><strong>Significance:</strong> Comprehensive review of LT for non-HCC tumors including CRLM, cholangiocarcinoma, and neuroendocrine tumors.</p>
                </div>
            </section>

            <section class="section">
                <h2>Landmark Clinical Trials</h2>

                <div class="trial-item">
                    <h3>TransMet Trial (2024) - First RCT</h3>
                    <p><strong>Title:</strong> Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial</p>
                    <p><strong>Authors:</strong> Adam R, Piedvache C, Chiche L, et al.</p>
                    <p><strong>Journal:</strong> The Lancet, 2024; 404(10457):1107-1118</p>
                    <p><strong>Key Result:</strong> 5-year OS 56.6% (LT + Chemo) vs. 12.6% (Chemo alone); HR 0.37 (p=0.0003)</p>
                    <p><strong>ClinicalTrials.gov:</strong> NCT02597348</p>
                </div>

                <div class="trial-item">
                    <h3>SECA-I Trial (2013)</h3>
                    <p><strong>Title:</strong> Liver transplantation for patients with unresectable liver-only colorectal metastases</p>
                    <p><strong>Authors:</strong> Dueland S, et al.</p>
                    <p><strong>Key Result:</strong> 5-year OS 60% in 21 patients</p>
                    <p><strong>Significance:</strong> Pioneering study that reignited interest in LT for CRLM</p>
                </div>

                <div class="trial-item">
                    <h3>SECA-II Trial (2020)</h3>
                    <p><strong>Title:</strong> Liver transplantation for unresectable colorectal liver metastases in patients with extended criteria</p>
                    <p><strong>Authors:</strong> Smedman TM, et al.</p>
                    <p><strong>Key Result:</strong> 5-year OS up to 83% with stricter selection criteria</p>
                    <p><strong>Significance:</strong> Demonstrated that refined patient selection improves outcomes</p>
                </div>
            </section>

            <section class="section">
                <h2>Key Research Papers</h2>

                <div class="reference-list">
                    <div class="reference-item">
                        <h4>Long-Term Survival and Prognostic Factors (2023)</h4>
                        <p><strong>Dueland S, Smedman TM, Syversveen T, et al.</strong> Long-Term Survival, Prognostic Factors, and Selection of Patients With Colorectal Cancer for Liver Transplant: A Nonrandomized Controlled Trial. <em>JAMA Surgery</em>, 2023; 158(9):e232932.</p>
                        <p><strong>Key Findings:</strong> 10-year OS 88.9% (Oslo Score 0-1); median OS 60.3 months; identification of prognostic factors</p>
                    </div>

                    <div class="reference-item">
                        <h4>Molecular Prognostic Factors (2025)</h4>
                        <p><strong>Moosavi SH, Kryeziu K, Eilertsen IA, et al.</strong> Molecular prognostic factors for liver transplantation of unresectable metastatic colorectal cancer. <em>British Journal of Surgery</em>, 2025; 112(4):znaf072.</p>
                        <p><strong>Key Findings:</strong> RAS/TP53 co-mutations associated with median OS 21 months vs. 60 months; importance of molecular profiling</p>
                    </div>

                    <div class="reference-item">
                        <h4>Comparative Analysis: LT vs. PVE + Resection (2021)</h4>
                        <p><strong>Dueland S, Yaqub S, Syversveen T, et al.</strong> Survival Outcomes After Portal Vein Embolization and Liver Resection Compared With Liver Transplant for Patients With Extensive Colorectal Cancer Liver Metastases. <em>JAMA Surgery</em>, 2021; 156(6):550-557.</p>
                        <p><strong>Key Findings:</strong> LT 5-year OS 45.3% vs. PVE+LR 12.5% for HTL with left-sided primary tumors</p>
                    </div>

                    <div class="reference-item">
                        <h4>Current State in the United States (2023)</h4>
                        <p><strong>Sasaki K, Ruffolo LI, Kim MH, et al.</strong> The Current State of Liver Transplantation for Colorectal Liver Metastases in the United States: A Call for Standardized Reporting. <em>Annals of Surgical Oncology</em>, 2023; 30(6):3467-3475.</p>
                        <p><strong>Key Findings:</strong> 1-, 2-, 3-year OS 89.0%, 60.4%, 60.4%; 56.5% LDLT use; growing adoption in US centers</p>
                    </div>

                    <div class="reference-item">
                        <h4>Where Are We Now? (2022)</h4>
                        <p><strong>Chávez-Villa M, Ruffolo LI, Tomiyama K, Hernandez-Alejandro R.</strong> Where Are We Now With Liver Transplant for Colorectal Metastasis? <em>Current Transplantation Reports</em>, 2022; 9(4):273-282.</p>
                        <p><strong>Key Findings:</strong> Comprehensive review of current evidence, ongoing trials, and institutional experience</p>
                    </div>
                </div>
            </section>

            <section class="section">
                <h2>Ongoing Clinical Trials</h2>
                <p>Multiple prospective studies are currently investigating LT for CRLM. Below are some key trials:</p>

                <table class="data-table">
                    <tr>
                        <th>Trial Name</th>
                        <th>Country</th>
                        <th>Status</th>
                        <th>Primary Comparison</th>
                        <th>ClinicalTrials.gov ID</th>
                    </tr>
                    <tr>
                        <td><strong>SECA III</strong></td>
                        <td>Norway</td>
                        <td>Ongoing (2016-2027)</td>
                        <td>LT vs. Chemo + TACE/SIRT</td>
                        <td>NCT03494946</td>
                    </tr>
                    <tr>
                        <td><strong>EXCALIBUR 1+2</strong></td>
                        <td>Norway</td>
                        <td>Ongoing (2021-2026)</td>
                        <td>2nd-line Chemo + HAI or LT vs. Chemo alone</td>
                        <td>NCT04898504</td>
                    </tr>
                    <tr>
                        <td><strong>Toronto LDLT for UR CRLM</strong></td>
                        <td>Canada</td>
                        <td>Ongoing (2016-2025)</td>
                        <td>Living donor LT outcomes</td>
                        <td>NCT02864485</td>
                    </tr>
                    <tr>
                        <td><strong>LIVER-T(W)O-HEAL</strong></td>
                        <td>Germany</td>
                        <td>Ongoing (2018-2023)</td>
                        <td>LDLT with two-stage hepatectomy</td>
                        <td>NCT03488953</td>
                    </tr>
                    <tr>
                        <td><strong>SOULMATE</strong></td>
                        <td>Sweden</td>
                        <td>Ongoing (2020-2030)</td>
                        <td>Chemo + LT with extended criteria donors</td>
                        <td>NCT04161092</td>
                    </tr>
                    <tr>
                        <td><strong>MELODIC</strong></td>
                        <td>Italy</td>
                        <td>Ongoing (2020-2025)</td>
                        <td>LT from deceased donor vs. chemo</td>
                        <td>NCT04870879</td>
                    </tr>
                    <tr>
                        <td><strong>WCMC Pilot Registry</strong></td>
                        <td>United States</td>
                        <td>Ongoing (2020-2035)</td>
                        <td>Observational registry of LT for UR CRLM</td>
                        <td>NCT04742621</td>
                    </tr>
                </table>
            </section>

            <section class="section">
                <h2>Useful Tools and Calculators</h2>

                <div class="tool-item">
                    <h3>Oslo Score Calculator</h3>
                    <p>Use this scoring system to stratify patients:</p>
                    <ul>
                        <li>1 point: Largest tumor size ≥ 5.5 cm</li>
                        <li>1 point: Progressive disease on chemotherapy</li>
                        <li>1 point: CEA > 80 µg/L</li>
                        <li>1 point: Time from primary resection to LT < 2 years</li>
                    </ul>
                    <p><strong>Score 0-2:</strong> Favorable; <strong>Score 3-4:</strong> Unfavorable</p>
                </div>

                <div class="tool-item">
                    <h3>Fong Clinical Risk Score (FCRS)</h3>
                    <p>Alternative prognostic tool:</p>
                    <ul>
                        <li>1 point each: Node-positive primary, DFI < 12 mo, >1 tumor, CEA > 200 ng/mL, largest tumor > 5 cm</li>
                    </ul>
                    <p><strong>Score 0-2:</strong> Favorable; <strong>Score ≥3:</strong> Unfavorable</p>
                </div>

                <div class="tool-item">
                    <h3>PET-MTV Assessment</h3>
                    <p>Metabolic tumor volume measured on 18F-FDG PET/CT:</p>
                    <ul>
                        <li><strong>&lt; 70 cm³:</strong> Favorable (5-year OS 63.6%)</li>
                        <li><strong>≥ 70 cm³:</strong> Unfavorable (5-year OS 25%)</li>
                    </ul>
                </div>
            </section>

            <section class="section">
                <h2>Professional Organizations</h2>
                <ul>
                    <li><strong>International Hepato-Pancreato-Biliary Association (IHPBA):</strong> Published consensus guidelines on LT for CRLM</li>
                    <li><strong>American Society of Transplantation (AST):</strong> Resources on transplant oncology</li>
                    <li><strong>European Society for Organ Transplantation (ESOT):</strong> Information on transplant practices in Europe</li>
                    <li><strong>American Society of Clinical Oncology (ASCO):</strong> Colorectal cancer treatment guidelines</li>
                </ul>
            </section>

            <section class="section">
                <h2>Multidisciplinary Team Approach</h2>
                <p>Successful LT for CRLM requires collaboration among:</p>
                <ul>
                    <li><strong>Hepatobiliary Surgeons:</strong> Surgical expertise in liver transplantation</li>
                    <li><strong>Transplant Physicians:</strong> Perioperative management and immunosuppression</li>
                    <li><strong>Medical Oncologists:</strong> Systemic therapy and response assessment</li>
                    <li><strong>Radiologists:</strong> Imaging interpretation and disease burden assessment</li>
                    <li><strong>Pathologists:</strong> Tumor characteristics and molecular profiling</li>
                    <li><strong>Colorectal Surgeons:</strong> Primary tumor management</li>
                    <li><strong>Interventional Radiologists:</strong> Locoregional therapies if needed</li>
                </ul>
            </section>

            <section class="section">
                <h2>Additional Reading</h2>
                <p>For a comprehensive review of the evidence, download or read the full academic review article:</p>
                <p><strong>Title:</strong> Liver Transplantation for Permanently Unresectable Colorectal Liver Metastases: A Review of Evolving Evidence, Selection Criteria, and Future Directions in Transplant Oncology</p>
                <p><strong>Available:</strong> <a href="../review_article_crlm.md">Full Review Article (Markdown)</a></p>
            </section>

            <section class="section call-to-action">
                <h2>Questions or Feedback?</h2>
                <p>This resource is designed to support clinical decision-making for transplant teams. For specific patient cases, please consult with your multidisciplinary team and refer to the latest published guidelines.</p>
            </section>
        </div>
    </main>

    <!-- Footer -->
    <footer class="footer">
        <div class="container">
            <p>&copy; 2025 CRLM LT Clinical Resource. Evidence-based information for transplant teams.</p>
            <p class="author"><strong>Created by:</strong> Tor Magnus Smedman, MD PhD | Transplant Oncology Research Group, Oslo University Hospital</p>
            <p class="disclaimer">This resource is for educational purposes. Clinical decisions should be made in consultation with a multidisciplinary team.</p>
        </div>
    </footer>

    <script src="../js/main.js?v=1765115033437"></script>
    <script>
        // Hamburger menu toggle
        const hamburger = document.getElementById("hamburger");
        const navMenu = document.getElementById("navMenu");
        
        if (hamburger && navMenu) {
            hamburger.addEventListener("click", function() {
                navMenu.classList.toggle("active");
                hamburger.classList.toggle("active");
            });
            
            // Close menu when a link is clicked
            const navLinks = navMenu.querySelectorAll("a");
            navLinks.forEach(link => {
                link.addEventListener("click", function() {
                    navMenu.classList.remove("active");
                    hamburger.classList.remove("active");
                });
            });
        }
    </script>
</body>
</html>
